Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Cholangiocarcinoma × Immunotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Sarcoma 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Head and Neck Neoplasms 1 Glioblastoma 1 Cholangiocarcinoma 1 Brain Neoplasms 1

Interventions

Gemcitabine 25 Cisplatin 17 pembrolizumab 6 Capecitabine 5 Fluorouracil 4 durvalumab 3 Taxes 3 Oxaliplatin 3 Carboplatin 3 130-nm albumin-bound paclitaxel 3 tremelimumab 2 trametinib 2 pemigatinib 2 ivosidenib 2 infigratinib 2 derazantinib 2 atezolizumab 2 Radiotherapy 2 Radiosurgery 2 Platinum 2 Nivolumab 2 Liver Transplantation 2 Leucovorin 2 Drug Therapy 2 Albumin-Bound Paclitaxel 2 1,2-diaminocyclohexaneplatinum II citrate 2 vandetanib 1 tucatinib 1 trifluridine tipiracil drug combination 1 tofacitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡